The pharmaceutic capitalization of a natural, marine active principle through in vitro anti-citokinic and proliferative mechanisms of HC-OA osteoarthritic chondrocytes

• DOI: 10.37897/rjmp.2019.1.9
• Publication Date: 2020-04-23T09:56:08Z
• Authors: Laura Olariu; ; Brindusa Dumitriu; ; Toma Papacocea; ; ; Diana Manuela Ene
• Keywords: Medicine (General); osteoarthritic chondrocytes; proliferation; R; degenerative osteoarthicular diseases; pro-inflammatory cytokines; 3. Good health; 03 medical and health sciences; small sea fish extract; R5-920; 0302 clinical medicine; Medicine

Osteoarthritis (OA) as a multi-factorial disease that features interrelated mechanisms (senescence/ apoptosis, proliferation, decreased synthesis of matrix proteins, activation degrading enzymes, inflammation) and diversity cells involved in bone cartilage metabolism: chondrocytes, osteoblasts, osteoclasts etc. A complete pharmaceutical solution remains an unsolved question this interdisciplinary field research.We focused our approach on osteoarthritic primary chondrocytes HC-OA (Cell Application), exploring cell line the small sea fish extract's potential to improve proliferation rate stop cytokines pro-inflammatory signaling.Previous research results have shown important therapeutic extract, restoring intrinsic functionality through its correlative effects: antioxidant anti-inflammatory action, stimulatory activity matriceal proteins homeostasis.In context degradative stimulation with IL1β, extract prove counteracting "in vitro" effect, proliferative capacity inhibiting IL8 release, implication several degradation pathways: MMP13 activation, neutrophils' accumulation, synovium leucocytes well hypertrophic differentiation processes chondrocytes.